Colorectal Cancer
Conditions
Brief summary
This study is aimed to evaluate the performance of the Micromedic CD24 assay in identifying colorectal adenoma using Western blot and ELISA assays. These assays are designed to detect CD24 protein in peripheral blood leukocytes (PBL). Elevated levels of CD24 may be indicative of colorectal adenoma (inclusive of optically detectable early adenoma to late adenoma, and cancer).
Interventions
OTHERblood-sample based diagnostic assay
A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
Sponsors
Meir Medical Center
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subject is 50 years old and above * Subject is asymptomatic and referred for regular recommended screening colonoscopy or subject is referred due to suspicion of colon cancer, prior to beginning of any treatment (enriched population) * Subject signed the informed consent
Exclusion criteria
* Subject has been previously diagnosed with any type of cancer * Subject has been previously diagnosed with a colorectal abnormality such as colorectal adenoma, hyperplastic polyp or carcinoma * Blood sample was not collected on the day of colonoscopy and prior to colonoscopy * Subject has first degree family history of colorectal cancer * Subject has active infection or inflammation as determined clinically at screening * Subject is currently taking medications related to the previous
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Colonoscopy and CD24 assay correlation | 12 months |
Countries
Israel
Outcome results
None listed